RIPK1 and neoplasm: More importantly, scCRISPR screen platforms enable us to determine the heterogeneous changes of gene expression in Prmt1, Ripk1 or Axl knockout (KO) tumor cells in the presence of immune attack, which cannot be easily assessed by bulk RNA-seq.